RxDoctor Payments Data

Nikou Gougol, MD

Internal Medicine · Brooklyn, NYNPI 1285298810

Payments from drug & device makers

$768in general payments, 2019–2025

Across 31 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$137
  • Exact Sciences$124
  • Xeris Pharmaceuticals, Inc.$112
  • Amgen$57
  • Pfizer$54
  • Averitas Pharma Inc.$53
  • plus $231 from 9 others

What the payments were for

  • Food & beverage$768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$768 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$14,368
Medicare patients
66
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium171$203,607
OzempicSemaglutide126$133,830
JardianceEmpagliflozin114$93,712
Metformin Er GastricMetformin Hcl66$82,971
MounjaroTirzepatide58$59,428
EliquisApixaban57$41,356
TrulicityDulaglutide25$38,363
FarxigaDapagliflozin Propanediol45$31,730
EntrestoSacubitril/Valsartan43$30,850
JanuviaSitagliptin Phosphate39$30,772
XareltoRivaroxaban34$24,215
RybelsusSemaglutide22$23,981
Oxiconazole Nitrate65$21,712
Lactulose23$21,198
JanumetSitagliptin Phos/Metformin Hcl17$15,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$42$157,811148 claims
Lilly USA, LLCMounjaro, Trulicity$137$97,79183 claims
MerckJanuvia, Janumet$19$45,94256 claims
PfizerEliquis$54$41,35657 claims
AstraZenecaFarxiga, Symbicort$16$34,36056 claims
GSKIncruse Ellipta$22$5,54715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →